Pub. Date : 2019
PMID : 31781324
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Metformin Activates the Protective Effects of the AMPK Pathway in Acute Lung Injury Caused by Paraquat Poisoning. | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |
| 2 | Objective: To observe whether metformin (MET) plays a protective role in acute lung injury (ALI) induced by paraquat (PQ) poisoning in rats by activating the AMPK/NF-kappaB signaling pathway. | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |
| 3 | Objective: To observe whether metformin (MET) plays a protective role in acute lung injury (ALI) induced by paraquat (PQ) poisoning in rats by activating the AMPK/NF-kappaB signaling pathway. | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |
| 4 | Results: Compared with the PQ group, the MET treatment group showed significantly (1) reduced lung wet/dry ratio (W/D: 4.67 +- 0.31 vs. 5.45 +- 0.40, P < 0.001), (2) reduced pathological changes in lung tissue, (3) decreased MDA levels (nmol/mg prot: 2.70 +- 0.19 vs. 3.08 +- 0.15, P < 0.001) and increased SOD and GSH-Px activities (U/mg prot: 76.17 +- 5.22 vs. 45.23 +- 6.58, 30.40 +- 2.84 vs. 21.00 +- 3.20; all P < 0.001) in lung tissue homogenate, (4) reduced levels of IL-1beta, IL-6, and TNF-alpha in lung tissue homogenates (pg/mL: 47.87 +- 5.06 vs. 66.77 +- 6.55; 93.03 +- 7.41 vs. 107.39 +- 9.81; 75.73 +- 6.08 vs. 89.12 +- 8.94; all P < 0.001), (5) increased activity of RLE-6TN cells (%: 0.69 +- 0.09, 0.76 +- 0.06, and 0.58 +- 0.03 vs. 0.50 +- 0.05; all P < 0.05), (6) decreased protein levels of phospho-NF-kappaBp65 in lung homogenates and RLE-6TN cells (p-NF-kappaB/NF-kappaB: 0.47 +- 0.09 vs. 0.81 +- 0.13; 0.26 +- 0.07 vs. 0.79 +- 0.13; all P < 0.01), and (7) upregulated protein expression of phospho-AMPK in lung homogenates and RLE-6TN cells (p-AMPK/AMPK: 0.88 +- 0.05 vs. 0.36 +- 0.12; 0.93 +- 0.03 vs. 0.56 +- 0.15; all P < 0.01). | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |
| 5 | Results: Compared with the PQ group, the MET treatment group showed significantly (1) reduced lung wet/dry ratio (W/D: 4.67 +- 0.31 vs. 5.45 +- 0.40, P < 0.001), (2) reduced pathological changes in lung tissue, (3) decreased MDA levels (nmol/mg prot: 2.70 +- 0.19 vs. 3.08 +- 0.15, P < 0.001) and increased SOD and GSH-Px activities (U/mg prot: 76.17 +- 5.22 vs. 45.23 +- 6.58, 30.40 +- 2.84 vs. 21.00 +- 3.20; all P < 0.001) in lung tissue homogenate, (4) reduced levels of IL-1beta, IL-6, and TNF-alpha in lung tissue homogenates (pg/mL: 47.87 +- 5.06 vs. 66.77 +- 6.55; 93.03 +- 7.41 vs. 107.39 +- 9.81; 75.73 +- 6.08 vs. 89.12 +- 8.94; all P < 0.001), (5) increased activity of RLE-6TN cells (%: 0.69 +- 0.09, 0.76 +- 0.06, and 0.58 +- 0.03 vs. 0.50 +- 0.05; all P < 0.05), (6) decreased protein levels of phospho-NF-kappaBp65 in lung homogenates and RLE-6TN cells (p-NF-kappaB/NF-kappaB: 0.47 +- 0.09 vs. 0.81 +- 0.13; 0.26 +- 0.07 vs. 0.79 +- 0.13; all P < 0.01), and (7) upregulated protein expression of phospho-AMPK in lung homogenates and RLE-6TN cells (p-AMPK/AMPK: 0.88 +- 0.05 vs. 0.36 +- 0.12; 0.93 +- 0.03 vs. 0.56 +- 0.15; all P < 0.01). | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |
| 6 | Results: Compared with the PQ group, the MET treatment group showed significantly (1) reduced lung wet/dry ratio (W/D: 4.67 +- 0.31 vs. 5.45 +- 0.40, P < 0.001), (2) reduced pathological changes in lung tissue, (3) decreased MDA levels (nmol/mg prot: 2.70 +- 0.19 vs. 3.08 +- 0.15, P < 0.001) and increased SOD and GSH-Px activities (U/mg prot: 76.17 +- 5.22 vs. 45.23 +- 6.58, 30.40 +- 2.84 vs. 21.00 +- 3.20; all P < 0.001) in lung tissue homogenate, (4) reduced levels of IL-1beta, IL-6, and TNF-alpha in lung tissue homogenates (pg/mL: 47.87 +- 5.06 vs. 66.77 +- 6.55; 93.03 +- 7.41 vs. 107.39 +- 9.81; 75.73 +- 6.08 vs. 89.12 +- 8.94; all P < 0.001), (5) increased activity of RLE-6TN cells (%: 0.69 +- 0.09, 0.76 +- 0.06, and 0.58 +- 0.03 vs. 0.50 +- 0.05; all P < 0.05), (6) decreased protein levels of phospho-NF-kappaBp65 in lung homogenates and RLE-6TN cells (p-NF-kappaB/NF-kappaB: 0.47 +- 0.09 vs. 0.81 +- 0.13; 0.26 +- 0.07 vs. 0.79 +- 0.13; all P < 0.01), and (7) upregulated protein expression of phospho-AMPK in lung homogenates and RLE-6TN cells (p-AMPK/AMPK: 0.88 +- 0.05 vs. 0.36 +- 0.12; 0.93 +- 0.03 vs. 0.56 +- 0.15; all P < 0.01). | Metformin | protein kinase AMP-activated catalytic subunit alpha 2 | Rattus norvegicus |